Pancreatic Cancer Research

ResearcherUniversity of AntwerpActive in the last 2 years

Hans Prenen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8802-7352; OpenAlex author ID A5060176567. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 2 papers

Papers 8

  1. Protein-level profiling of TIGIT axis components in human PDAC reveals immune-suppressive expression patterns. Co-author DOI 10.1007/s00262-026-04343-w↗
  2. IL-15 boosts mesothelin- and CD70-CAR NK cell potency in PDAC without added benefit from dual targeting. Co-author DOI 10.1016/j.omton.2026.201316↗
  3. CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1. Co-author DOI 10.1016/j.xcrm.2025.102407↗
  4. Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre… Co-author DOI 10.1016/s1470-2045(24)00263-8↗
  5. Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by… Co-author DOI 10.1186/s13046-024-03012-z↗
  6. Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer. Co-author DOI 10.1038/s41698-023-00480-y↗
  7. Targeting hedgehog signaling in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pharmthera.2022.108107↗
  8. Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. Last author DOI 10.3390/cancers13050987↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Geert Roeyen · 6 shared papers, 2021–2026 · strength 1.05
  2. Marc Peeters · 5 shared papers, 2021–2026 · strength 0.83
  3. Evelien Smits · 5 shared papers, 2021–2026 · strength 0.81
  4. Jonas R.M. Van Audenaerde · 4 shared papers, 2021–2026 · strength 0.72
  5. Christophe Deben · 4 shared papers, 2021–2026 · strength 0.66
  6. Delphine Quatannens · 3 shared papers, 2021–2026 · strength 0.50
  7. Emmanuel Mitry · 2 shared papers, 2024–2025 · strength 0.36
  8. Jean‐Frédéric Blanc · 2 shared papers, 2024–2025 · strength 0.36
  9. Jean‐Luc Van Laethem · 2 shared papers, 2024–2025 · strength 0.36
  10. Karen Paula Geboes · 2 shared papers, 2024–2025 · strength 0.36
  11. Lorenzo Pilla · 2 shared papers, 2024–2025 · strength 0.36
  12. Roberto Pazo-Cid · 2 shared papers, 2024–2025 · strength 0.36
  13. Aurélien Lambert · 2 shared papers, 2024–2025 · strength 0.36
  14. Jaime Feliú · 2 shared papers, 2024–2025 · strength 0.36
  15. Philippe Alexandre Cassier · 2 shared papers, 2024–2025 · strength 0.36
  16. Teresa Mercade Macarulla · 2 shared papers, 2024–2025 · strength 0.36
  17. Maxim Le Compte · 2 shared papers, 2023–2024 · strength 0.33
  18. Andreas Domen · 2 shared papers, 2021–2023 · strength 0.26
  19. Timon Vandamme · 2 shared papers, 2021–2023 · strength 0.26
  20. Laura Gehrcken · 1 shared paper, 2026 · strength 0.22
  21. Eileen Mary O'Reilly · 1 shared paper, 2025 · strength 0.19
  22. Gregory Lawrence Beatty · 1 shared paper, 2025 · strength 0.19
  23. Sofía L. J. Peeters · 1 shared paper, 2023 · strength 0.15
  24. Sara R. Zanivan · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.